Literature DB >> 8430673

Serum albumin concentration-related Health Care Financing Administration quality assurance criterion is method-dependent: revision is necessary.

C R Blagg1, R J Liedtke, J D Batjer, B Racoosin, T K Sawyer, M J Wick, L Lawson, K Wilkens.   

Abstract

The objective of this study was to examine quantitative differences between the two commonly used methods for determining serum albumin concentration, bromcresol green (BCG) and bromcresol purple (BCP), in normal subjects and in 235 unselected dialysis patients in view of recently established Health Care Financing Administration (HCFA) quality assurance review criteria. The mean of normal results by the BCG method was 4.4 g/dL, and 97.5% of values were 3.8 g/dL or higher. The mean of normal results by the BCP method was 3.9 g/dL, and 97.5% of values were 3.3 g/dL or higher. Serum albumin concentrations in samples from the dialysis patients had respectively lower mean values by both methods. For the BCG method, the mean was 3.8 g/dL, and 82% of values were 3.5 g/dL or higher; for the BCP method, the mean was 3.3 g/dL, and 82% of values were 3.0 g/dL or higher. Likewise, for the reference immunonephelometric procedure, the mean value for the dialysis patients was 3.3 g/dL, and 82% of values were 3.0 g/dL or higher. For the samples from the dialysis patients, in comparison with the immunonephelometric method, the BCG method exhibited both constant (intercept = 9.3 g/L) and proportional error (slope = 0.87). The mean albumin value for the BCG method was 3.8 g/dL, 15% higher. In contrast, the BCP method compared closely with the reference method: slope = 1.00, intercept = 0.8 g/L, mean x = 3.3 g/dL, mean y = 3.3 g/dL. The HCFA quality assurance criteria are valid only for the BCG method.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8430673     DOI: 10.1016/s0272-6386(12)81084-5

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

1.  Reference distributions for the negative acute-phase proteins, albumin, transferrin, and transthyretin: a comparison of a large cohort to the world's literature.

Authors:  R F Ritchie; G E Palomaki; L M Neveux; O Navolotskaia
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

2.  Ethnic disparity in outcomes for pediatric peritoneal dialysis patients in the ESRD Clinical Performance Measures Project.

Authors:  Meredith A Atkinson; Alicia M Neu; Barbara A Fivush; Diane L Frankenfield
Journal:  Pediatr Nephrol       Date:  2007-09-18       Impact factor: 3.714

3.  Hypoalbuminemia and early mortality after lung transplantation: a cohort study.

Authors:  M R Baldwin; S M Arcasoy; A Shah; P C Schulze; J Sze; J R Sonett; D J Lederer
Journal:  Am J Transplant       Date:  2012-02-15       Impact factor: 8.086

4.  Anemia in pediatric dialysis patients in end-stage renal disease network 5.

Authors:  Jeffrey J Fadrowski; Susan L Furth; Barbara A Fivush
Journal:  Pediatr Nephrol       Date:  2004-07-06       Impact factor: 3.714

5.  Disparate outcomes in pediatric peritoneal dialysis patients by gender/race in the End-Stage Renal Disease Clinical Performance Measures project.

Authors:  Meredith A Atkinson; Alicia M Neu; Barbara A Fivush; Diane L Frankenfield
Journal:  Pediatr Nephrol       Date:  2008-05-16       Impact factor: 3.714

6.  Trends and outcomes associated with serum albumin concentration among incident dialysis patients in the United States.

Authors:  George A Kaysen; Kirsten L Johansen; Su-Chun Cheng; Chengshi Jin; Glenn M Chertow
Journal:  J Ren Nutr       Date:  2008-07       Impact factor: 3.655

7.  Evaluation of the Beckman Coulter DxC 700 AU chemistry analyzer.

Authors:  V J Bush; C Smola; P Schmitt
Journal:  Pract Lab Med       Date:  2019-11-20

Review 8.  Clinical outcomes in pediatric hemodialysis patients in the USA: lessons from CMS' ESRD CPM Project.

Authors:  Alicia M Neu; Diane L Frankenfield
Journal:  Pediatr Nephrol       Date:  2008-05-29       Impact factor: 3.714

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.